The same 1.1ASML antibody was used for the construction of a bispecific F(ab9)2 antibody conjugate (BAC) which recognizes both the CD44v6 tumor cell moiety and the complement receptor CR3 on macrophages in order to redirect and induce efficient macrophage-mediated tumor cytotoxicity. Here, CRIPTO3 is linked to neoplasm.